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Abstracts 
Background: Although the heterogeneity in treatment-resistant schizophrenia (TRS) is key to 
understanding its etiology and developing more effective treatment strategies, subtyping in TRS 
from the viewpoint of clinical characteristics and disease course has not been established. 
Dopamine supersensitivity psychosis (DSP), related to longstanding neuroleptic treatment, 
presents unstable positive symptoms and tardive dyskinesia, likely meeting the TRS criteria. It 
is necessary to explore the implications of DSP in TRS. Methods: TRS patients were recruited 
from 3 hospitals for the present study. Through direct interviews and chart reviews, all patients 
were judged as either TRS or not, and their past/present histories of DSP episode(s) were 
investigated. We then compared each factor between the groups with and without DSP 
episode(s). Results: Out of 611 patients screened, 146 patients met the criteria for TRS and were 
included in the present analysis. These were divided into groups with and without DSP, 
comprising 101 (69.2%) and 45 patients (30.8%), respectively. No difference between the two 
groups was observed for most other clinical characteristics. Subtypes of DSP episodes, i.e., 
rebound psychosis and tolerance to antipsychotic effects, were experienced in 60% and 68% of 
the patients in the DSP group, respectively. Furthermore, seventy-five percent of all DSP 
episodes resulted in hospital admission. Conclusions: The present study revealed that 
approximately 70% of TRS patients experienced at least one DSP episode throughout their 
illness history, strongly suggesting that DSP, which is closely linked to antipsychotic treatment, 
is profoundly involved in the etiology of TRS.  
 
Keyword: Antipsychotics; Clinical course; Dopamine D2 receptor; Prognosis 
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1. Introduction 
Schizophrenia is a serious mental disorder with an approximately 1% lifetime prevalence rate. 
Its onset generally occurs in adolescence or early adulthood, and it subjects patients to profound 
distress throughout their lifetimes. Although pharmacotherapy with neuroleptics has been a 
main strategy for in treating this disorder, sufficient symptom recovery is attained only in 
30-45% of patients.1,2 Patients whose positive symptoms are not successfully relieved in spite of 
sufficient pharmacotherapy are defined as having treatment-resistant schizophrenia (TRS),3,4 
and the diagnostic criteria proposed by Kane and colleges3 has broadly prevailed. Among 
treatment-resistant patients, some do not respond significantly to antipsychotic(s) from the early 
disease phase5 while others progress gradually into the refractory state through their disease 
course.6 Furthermore, though clozapine has been established as the only effective agent for 
treatment-resistant cases, some patients respond poorly even to clozapine7; these patients have 
been called “super-treatment refractory schizophrenia”.8 These notions suggest that the patient 
group with TRS contains diverse disease subtypes in terms of treatment responsiveness and 
disease course. However, the heterogeneity of TRS has remained unresolved, despite the fact 
that knowledge on the subtypes and their etiologies is important for the development of 
preventive and treatment strategies. 
Some studies have reported that a significant proportion of patients with schizophrenia 
take high doses of multiple antipsychotics in clinical practice,9 suggesting difficulty with 
symptom control. Longstanding excessive blockade of neurotransmitters not only produces 
several adverse events such as extrapyramidal symptoms and cognitive dysfunctions, but also 
possibly worsens the disease prognosis.10,11 In particular, dopamine supersensitivity psychosis 
(DSP), known as neuroleptic-induced supersensitivity psychosis,12 has recently been classified 
as iatrogenic supersensitivity psychosis by some researchers.13 The psychotic state is closely 
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related to up-regulation of dopamine D2 receptors by the excessive blockade of 
neuroleptic(s).14,15 Clinically, the psychosis is characterized by tardive dyskinesia, a relapse 
episode immediately following treatment discontinuation (rebound psychosis) and developed 
tolerance to antipsychotic effects despite continuous treatment.16,17 That is, patients experiencing 
DSP episodes likely progress into treatment resistance, responding less and less to even higher 
doses of neuroleptics.15       
Chouinard and Chouinard stated that about 50% of patients with TRS are involved in the 
dopamine supersensitivity state.18 This speculation was derived from the frequent rates of 
tardive dyskinesia, which occurs in treatments previously reported by several antipsychotics. 
However, no study has reported the frequency rate of all of DSPs including rebound psychosis 
and tolerance to antipsychotic effects as well as tardive dyskinesia; thus, the essential role of 
DSP in the etiology of TRS has been unknown. On the other hand, Chouinard defined patients 
with continuous psychotic symptoms responding less to neuroleptics as being excluded from 
DSP.16 Therefore, patients with deficit syndrome, presenting primary and continuous negative 
symptoms, were reported to be refractory to several antipsychotics 19,20 and thus such type of 
patients could be included in TRS. 
The present study aims to compare the clinical characteristics of patient groups with and 
without DSP among patients with TRS by examining the history of their symptoms; through 
this analysis, we explored the role of DSP in TRS.  
 
2. Methods 
2.1. Subjects 
The present study was conducted in three psychiatric hospitals. The study protocol was 
approved by the ethics committees of all relevant facilities and was conducted in accordance 
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with the Helsinki declaration. All 611 patients diagnosed as having schizophrenia or 
schizoaffective disorder (DSM-IV-TR) in either the outpatients or inpatient divisions of the 
research facilities were screened as candidate participants. Among them, a total of 202 patients 
were selected as meeting the TRS criteria described in the next paragraph (Fig. 1). Both oral and 
written informed consents were given from the patients or their guardians such as parents or 
spouse, if the patient was judged by the physician or the researcher to be unable to understand 
well the content of the present study. On that basis, we conducted an interview with each patient 
and/or his/her guardian(s) to assess whether the patient actually meet the TRS criteria and to 
evaluate symptom severity. Patients with comorbidities like organic brain disease, mental 
retardation and substance dependence of alcohol or any illegal drug were diagnosed according 
to DSM-IV-TR and from available medical records, and were excluded from the present study.   
A diagnosis of TRS was defined according to Broad Defensible Criteria21 with cases meeting 
at least one of the two following criteria: 1) In spite of appropriate pharmacotherapy with at 
least two antipsychotics from different chemical classes, the mean global assessment of 
functioning (GAF) prior to the most recent year did not exceed 60 points. Appropriate 
pharmacotherapy for a given agent is defined as 600 mg or greater chlorpromazine-equivalent 
dosage for at least 4 weeks. 2) Tardive dyskinesia with moderate or greater severity was not 
ameliorated by treatment, resulting in profound distress for the patient. With respect to patients 
treated with clozapine, all cases were assessed prior to initiation of clozapine, since clozapine 
was clinically available only 3 years ago in Japan; thus, for almost all patients, the period of the 
present survey coincides with clinical consideration of clozapine initiation. 
 
2.2. Symptom measurement 
2.2.1. Dopamine supersensitivity psychosis 
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For each patient potentially meeting the study criteria, we reviewed in detail clinical medical 
records and judged whether the patient had a past history of DSP, according to the criteria 
shown in Table 1. These criteria were developed by our group, but were slightly modified from 
the original criteria proposed by Chouinard.16 Briefly, the criteria focus on three factors as 
follows; at least one of the three criteria must be applicable at all times. 1) Rebound psychosis: 
an acute relapse or exacerbation of psychosis appearing after a dose reduction or discontinuation 
of antipsychotics, within 6 weeks for oral medication or 3 months for intramuscular medication. 
2) Developed tolerance to antipsychotic(s) effect: an acute relapse or exacerbation of psychosis 
occurs, independent of a dose reduction or discontinuation of antipsychotic therapy and a stable 
psychotic state, or the relapse episodes cannot be successfully controlled by a 20% increased 
titration of drug. 3) Presence of tardive dyskinesia. 
 
2.2.2. Other general measurements 
Through an interview for each patient, we evaluated the patient’s present clinical status with 
Brief Psychiatric Rating Scale,22 GAG, Clinical Global Impression-Severity (CGI-S) and 
Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS).23 
 
2.2.3. Clinical information on disease course 
To explore the hypothesis that DSP was profoundly affected by long-term antipsychotic(s) use, 
the present study examined each patient’s response to the initial treatment, in the patient group 
whose clinical records throughout their treatment histories were available. To subsequently meet 
the criteria of TRS for patients with DSP, the patient needed to experience a process into 
refractoriness including relapse episodes. That is, they could present at a high rate in their 
disease course, rebound psychosis and/or develop tolerance to antipsychotics. When assessing 
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good response to the initial treatment, we sought clear evidences in both the clinical record and 
direct interview with the patient and family members of 1) disappearance of first psychotic 
symptoms, and/or 2) good recovery in social daily living for at least three months following the 
termination of the first episode psychosis.    
     In addition, we assessed the structure of negative symptoms for all participants and 
judged whether each patient was or was not meeting the deficit syndrome,19 in order to 
demonstrate that the lowered GAF (<60) as evidence for “treatment-resistant schizophrenia” 
was caused by positive symptoms including DSP episode(s), but not simply by negative 
symptoms. Whereas patients with deficit syndrome present primary negative symptoms and 
cognitive impairment for a long-term duration,20 in patients with TRS the effects of secondary 
negative symptoms and cognitive impairments caused by extrapyramidal symptoms must be 
evaluated because of their lowered GAF, since these patients generally take high doses of 
antipsychotic(s) for a long time. In evaluating primary negative symptoms, we used the 
Schedule for the Deficit Syndrome (SDS),24 the Scale for the Assessment of Negative 
Symptoms (SANS),25 The Calgary Depression Scale for Schizophrenia-Japanese version 
(J-CDSS)26 and Hospital Anxiety, Depression Scale (HADS) 27 and DIEPSS. 
Upon these assessments, four researchers (T.S., N.K., H.Y., and M.T.) conducted several 
training sessions prior to the study and actually evaluated 20 patients together. Following these 
joint assessments, each of two researchers among four members evaluated the same participant 
in each research facility. The inter-rater reliabilities were over 0.85 throughout all measurement 
items. If judgments concerning TRS, DSP and deficit syndrome were divided among the raters, 
the two researchers tried to discuss with the patient’s physician and thereby reached consensus 
on a judgment. Eight patients whose clinical records were not sufficiently available were 
excluded from the final analysis.    
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2.3. Statistical analysis 
We used SPSS ver. 19.0 (IBM, NY, US) for the statistical analysis in the present study. We 
applied Student’s T test for continuous variables and chi-square test for categorical variables. To 
analyze the difference among three groups we applied ANOVA. 
 
3. Results 
All 611 patients in the research facilities were screened; among them, 146 TRS patients were 
included in the final analysis (Fig. 1).  
 
3.1. Cross-sectional evaluation: comparison between patients with and without DSP 
Of the TRS patients, 101 (69.2%) were judged as having a history of DSP according to the 
criteria (Table 2). There were no significant differences in age, gender, family history, diagnosis, 
age at onset, illness duration and numbers of admission, between the groups with and without 
DSP episodes. Furthermore, no difference in BPRS total score, positive symptoms, GAF or CGI 
was observed between the groups. Negative symptoms in the patient group without DSP tended 
to be higher than that in patients with DSP. DIEPSS scores of total and tardive dyskinesia in the 
patient group with DSP were significantly greater than those in the patients without DSP. 
Whereas 28.7% (N=29) of DSP patients were judged as having deficit syndrome, 57.8% (N=26) 
of non-DSP patients were judged as having deficit syndrome (P<0.01).  
When participants were divided into those with and without deficit syndrome, the relevant 
measurements in patients with and without deficit syndrome were as follow: SDS: 15.6±5.2 vs. 
5.2±3.6, P<0.001; SANS: 84.5±28.9 vs. 45.2±20.8, P<0.001; J-CDSS: 3.12±3.60 vs. 4.09
±2.51, P>0.05; HADS: 14.6±7.5 vs. 12.2±8.1, P>0.05; DIEPSS: 6.78±5.07 vs. 5.63±4.34, 
P>0.05, respectively. That is, negative symptom scores were significantly higher in those with 
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deficit syndrome than in those without, while scores for depression, anxiety and extrapyramidal 
symptoms did not differ between the two groups. 
In the patients with DSP, each episode of rebound psychosis, tolerance to antipsychotic 
effect and tardive dyskinesia was observed in approximately 50% of the patient group. The 
patients in the group with DSP experienced a mean 1.71±1.35 episodes of any DSP (range: 
1-20). When the patient group was classified based on the relevant numbers of DSP subtypes (1, 
2, or 3), among patients with any 1 subtype, any 2 subtypes or all 3 subtypes, there were no 
differences in BPRS total, positive symptoms, negative symptoms, GAF, CGI or DIEPSS (data 
not shown). 
  
3.2. Longitudinal evaluation: symptomatic assessment throughout all of treatment duration 
In the present study, the number of patients for whom all treatment records from the initial 
admission to the present interview was 60 in the DSP group and 9 in the non-DSP group (Table 
3). Patients showing symptomatic or functional remission of their first-episode psychosis; i.e., a 
good response to the initial pharmacotherapy, comprised 25.4% (N=13) of the group with DSP. 
In the group without DSP, 2 out of 9 patients achieved such a recovery state. A total of 112 
episodes were observed over the entire treatment duration in the group (N=51) with DSP; 
among them, 84 episodes (75%) required hospital admission.     
 
4. Discussion 
The present study demonstrated that patients with DSP related to antipsychotic treatment 
comprised about 70% of the TRS patient group. No significant differences in clinical 
characteristics such as age, gender, illness duration, numbers of admission and present symptom 
severity were observed between the patient groups with and without DSP. However, the scores 
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of extrapyramidal symptoms and tardive dyskinesia in the patients with DSP were greater than 
those in the patients without DSP. These results suggested that the dopamine supersensitivity 
state could develop because of antipsychotic treatment, and in such patients, both neurological 
and symptomatic signs (tardive dyskinesia and repeated episodes of DSP, respectively) were 
observed, likely resulting in a treatment-resistant state. On the other hand, there were a greater 
number of patients with deficit syndrome among patients without DSP than those with DSP. The 
patients with deficit schizophrenia, who are known to be less responsive to neuroleptics, 
comprised 60.5% of the group without DSP; this syndrome is suggested to be an important part 
in TRS.  
DSP has been considered iatrogenic state.13 The higher level of tardive dyskinesia in the 
group with DSP compared to the group－despite similar levels of other general characteristics
－strongly suggested that the former group was more profoundly affected by neuroleptics. 
While their clinical courses reflected no difference in illness history such as age at onset, illness 
duration and total numbers of hospital admissions, significantly greater numbers of the patients 
with DSP experienced rebound psychosis and tolerance episodes to antipsychotics, with rates of 
59.4% and 67.3%, respectively. In the longitudinal analysis, moreover, 26.8% out of total 
hospital admissions experienced by the group with DSP were due to DSP episodes, suggesting 
that the individual episodes presented with significant severity. Schizophrenia is generally 
characterized by repeat relapse episodes28,29 and these relapses are relevant to the appearance of 
DSP.18 These well-known notions strongly supported the results of our present study. Taken 
together, patients with DSP could develop treatment resistance through the course of repeated 
supersensitivity episodes. 
The incidence rate of tardive dyskinesia has been reported to be 20-40%30,31; the 
approximately 30% rate in the present study is in accordance with that range. Chouinard and 
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Chouinard18 estimated that about 50% of all treatment-resistant cases were possibly caused by 
DSP, based on the incidence rates of tardive dyskinesia alone reported by multiple clinical 
studies. The present study revealed that 70% patients of TRS cohort experienced at least one 
episode of DSP. The difference between Chouinard’s speculation and our data would be 
explained by the diagnostic criteria of both TRS and DSP, particularly since the present survey 
for the latter included rebound psychosis and tolerance episodes to neuroleptics in addition to 
tardive dyskinesia. On the other hand, several studies have reported excessively high doses of 
antipsychotics in Japan32; such high dosages of neuroleptics likely produce a greater rate of 
DSP. 
Deficit schizophrenia presents meaningful functional decline by severe negative 
symptoms from the disease onset,33 and patients’ clinical states are relentlessly stable from 5 
years to 20 years over the disease course.20,34 In the present study 38.2% of patients among all of 
analyzed treatment-resistant patients met the criteria of deficit syndrome; in the group without 
DSP, that percentage jumped to 60.5%. These results suggested that deficit syndrome constitutes 
a subset of TRS and in assessing TRS for individual patient, evaluation of his/her negative 
symptoms is also important in considering the subsequent treatment strategy, in addition to 
applying the treatment-resistant criteria to the patient. On the other hand, 28.7% of patients with 
DSP in this study had deficit syndrome, as well having at least one DSP episode. Such patients 
correspond to those who deteriorate into deficit form by repeated dopamine supersensitivity 
episodes.20  
Good responders to initial treatment comprised only 26.0% of the group with DSP. The 
recovery rate seemed to be slightly low since the general recovery rate to first-episode psychosis 
has been reported to be 35.6%.35 The result suggested that the difficulty in treating positive 
symptoms from the initial pharmacotherapy to their first-episode psychosis likely led to higher 
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dosages of neuroleptics, resulting in the DSP state.   
In interpreting the results of the present study, several methodological problems must be 
considered. First, judgment of each DSP episode was conducted retrospectively from the 
individual’s medical records. If tardive dyskinesia was present but not documented by the 
patient’s clinician, the patient was incorrectly judged as being without tardive dyskinesia. Thus, 
positive data; e. g., the number of patients with DSP episodes, might be underestimated in the 
present study. Second, adherence to drug medication is little considered in recording patients’ 
information. It has been suggested that most patients practice only partial adherence.36 
Furthermore, partial adherence would result in the appearance of a DSP state such as rebound 
psychosis, indicating that the medication adherence level and the blockade of dopamine D2 
receptors by neuroleptic(s) are inextricably linked in the individual. Third, data of the general 
schizophrenia patient group were lacking and thus it may be difficult to explain how DSP 
episodes caused treatment-resistant status, from our data on TRS patients alone.  
In conclusion, 70% of TRS patients experienced DSP episode and each subtype, i.e., 
rebound psychosis, developed tolerance to antipsychotic(s) and tardive dyskinesia, was 
distributed similarly among the patient group with DSP. The former two episodes providing 
unstable and severer positive symptoms resulted in admitted treatment at a highly rate, 
suggesting that DSP episodes are involved in a refractory process into treatment resistance in 
schizophrenia. 
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Figure legends: 
Figure 1: Overview of participant flow 
 
 
 
 
 

Table 1: Criteria for dopamine supersensitivity psychosis in the present study 
(A) The patient must have a 3-month history of receiving antipsychotics 
(B) At least one of the following major criteria must be present at any time point during 
antipsychotic treatment: 
(1) Rebound psychosis episode:  
 reappearance of psychotic symptoms upon decrease or discontinuation of medication, 
within 6 weeks for oral medication, 3 months for i.m. depot medication; 
 reappearanced psychotic symptoms include new schizophrenia symptom(s) for the 
patient. 
(2) Developed tolerance to antipsychotic effect:  
 greater frequency of relapse (acute psychotic exacerbation) during continuous 
treatment with neuroleptics; 
 relapsed psychotic symptoms cannot be successfully controlled by overall 20% or 
more dosage increase of antipsychotic(s). 
    ＊The episode(s) of (1) and (2) are required to be observed following clinically “stable” status. 
(3) Tardive dyskinesia 
These criteria are according to the DSP research criteria proposed by Chouinard (1991)16 and are 
modified so as to made applicable to a retrospective chart review like the present study. 
Table 2: Clinical characteristics of TRS patients with/without DSP episode(s)  
 Patients 
with DSP 
(N=101) 
Patients 
without DSP 
(N=45) 
Statistic values
Age(range: y) 46.4 [±12.9] 45.4 [±10.7]  N.S. 
Age range (y) (19-78) (22-70)  
Sex (male/female) 57/44 29/16 N.S. 
Family history (none/F2/F3) 79/16/4 32/9/3  
Diagnosis (SZ/SAD) 99/2 42/3 N.S. 
TRS criteria (poor response/intolerance) 97/4 44/1  
Age at onset (y) 23.1 [±7.0] 24.5 [±8.5] N.S. 
Illness duration [y] 23.6 [±13.0] 22.1 [±12.8] N.S. 
Numbers of admission 5.3 [±6.3] 3.6 [±3.2] N.S. 
DSP episode  
Rebound psychosis
Tolerance to antipsychotic effect
Tardive dyskinesia
 
60 
68 
44 
 
- 
- 
- 
 
BPRS: total 19.5 [±9.6] 20.4 [±10.1] N.S. 
BPRS: positive symptoms 8.5 [±4.7] 8.5 [±5.4] N.S. 
BPRS: negative symptoms 4.0 [±3.8] 5.0 [±3.6] N.S. 
Deficit syndrome 29 26 P<0.01 
GAF 33.3 [±9.4] 33.6 [±10.8] N.S. 
CGI-S 4.9 [±1.0] 5.0 [±1.1] N.S. 
DIEPSS: total 6.8 [±4.9] 4.6 [±3.8] P<0.01 
DIEPSS: tardive dyskinesia 0.87 [±1.18] 0.04 [±0.21] P<0.01 
 
Table 3: Difference in treatment response during the disease course in patient groups 
with/without DSP episode(s) 
 Patients 
with DSP 
(N=51) 
Patients 
without DSP 
(N=9) 
Statistic 
values 
Good response in initial treatment 13 2 N.S. 
Hospital admission: 
Mean number of admissions/patient 
Total number of admissions/group 
 
6.2 [±8.1] 
314 
 
4.1 [±2.4] 
37 
 
N.S. 
- 
Number of patients with DSP episodes: 
Rebound psychosis
Tolerance to antipsychotic effect
Tardive dyskinesia
Total numbers of DSP episode/group 
(required admission) 
 
26 
29 
23 
112 
(84) 
 
- 
- 
- 
- 
(-) 
 
Deficit syndrome 11 4 N.S. 
 
